UBS Group
BIOA

UBS Group’s BioAge Labs BIOA Stock Holding History

UBS Group’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.52M Buy
102,926
+33,444
+48% +$604K ﹤0.01% 4897
2026
Q1 		$1.22M Buy
69,482
+39,603
+133% +$763K ﹤0.01% 5397
2025
Q4 		$395K Sell
29,879
-7,055
-19% -$62.5K ﹤0.01% 6218
2025
Q3 		$217K Buy
36,934
+14,022
+61% +$65.7K ﹤0.01% 6626
2025
Q2 		$94.6K Buy
22,912
+5,109
+29% +$20.6K ﹤0.01% 7283
2025
Q1 		$66.9K Sell
17,803
-86,088
-83% -$398K ﹤0.01% 7358
2024
Q4 		$602K Buy
+103,891
New +$1.79M ﹤0.01% 5711

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

UBS Group's BIOA Position: Q2 2026 in Review

UBS Group increased its BioAge Labs (BIOA) stake by 48% in Q2 2026, buying an estimated $604K and bringing the position to 102,926 shares worth $2.52M. The position accounts for ﹤0.01% of the portfolio, ranked #4897.

UBS Group first reported a position in BIOA in Q4 2024 and has held it in 7 quarters since. 150 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • UBS Group held 102,926 shares of BioAge Labs worth $2.52M as of Q2 2026.
  • UBS Group bought 33,444 BioAge Labs shares in Q2 2026, an estimated $604K.
  • BioAge Labs made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4897 holding.
  • UBS Group first reported a position in BioAge Labs in Q4 2024 and has held it in 7 quarters since.
  • 150 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.